Trial NCT02420717

View at ClinicalTrials.gov 
Org. Study IDs: 2014-0521
Secondary IDs: 2014-0521 NCI-2015-00779 P30CA016672

Last trial update was posted on 2023-12-04

MeSH Interventions

Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological BB 1101 Cortisone Cyclophosphamide Cytarabine Dasatinib Daunorubicin Dexamethasone Dexamethasone acetate Doxorubicin Immunoglobulins Leucovorin Liposomal doxorubicin Mercaptopurine Methotrexate Prednisone Rituximab Vincristine

MeSH Conditions

Leukemia Leukemia, Lymphoid Philadelphia Chromosome Precursor Cell Lymphoblastic Leukemia-Lymphoma Recurrence

Other Conditions

Recurrent B Acute Lymphoblastic Leukemia Recurrent Ph-Like Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia Refractory Ph-Like Acute Lymphoblastic Leukemia

Stopping Reasons

Study was closed early due to low accrual and lack of response.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID